Ardelyx, Inc.

ARDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-61.6M $-39.1M $-66.1M $-67.2M $-158.2M $-94.3M $-94.9M $-91.3M
Depreciation & Amortization $3.1M $2.1M $1.3M $1.1M $2.8M $2.5M $2.5M $2.7M
Depreciation $800.0K $500.0K $600.0K $700.0K $1.4M $1.8M $2.5M $2.7M
Amortization — — — — — — — —
Stock-Based Compensation $49.0M $37.4M $13.5M $10.8M $12.0M $10.6M $9.9M $9.2M
Net Cash from Operating Activities $-42.5M $-44.8M $-89.7M $-70.0M $-152.6M $-81.4M $-76.5M $-70.3M
Investing Activities
Capital Expenditures $1.5M $1.0M $344.0K $55.0K $1.9M $324.0K $325.0K $311.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-9.0M $-18.3M $-131.2M $18.4M $50.9M $-31.4M $23.4M $-29.9M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $54.5M $106.6M $146.3M $75.3M $83.0M $22.8M $155.5M $103.6M
Net Change in Cash $3.1M $43.5M $-74.7M $23.7M $-18.6M $-90.1M $102.4M $3.4M
Free Cash Flow $-44.0M $-45.8M $-90.1M $-70.1M $-154.4M $-81.8M $-76.8M $-70.6M
← Newer Page 1 of 2 Older →